Shots:

• The P-III (DERMIS 1 & 2) trials evaluate roflumilast (0.3%) in patients with PsO. The results showed that 40% vs 7% achieved IGA success @8wks., 48% vs 10% achieved IGA status of clear or almost clear
• Additionally, 69% vs 31% of patients achieved an improvement of four-points or more in itch (WI-NRS success), was well-tolerated with a favorable safety and tolerability profile
• The new post hoc analyses showed consistent efficacy regardless of BSA and efficacy, 47% vs 2% of patients with baseline BSA involvement >10% achieved IGA success, 37% vs 9% with baseline BSA of 5-10% while 40% vs 7% of patients with baseline BSA <5% with knee or elbow involvement

Ref: Arcutis | Image: Arcutis